Future Medicine Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2021	FY 2020	FY 2019
Period Ending	Mar '22 Mar 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	1,000	1,000	-	-
Cost of Revenue	-	-	-	26.94
Gross Profit	1,000	1,000	-	-26.94
Selling, General & Admin	1,834	1,860	1,693	1,998
Research & Development	5,791	5,375	3,881	4,846
Other Operating Expenses	16.65	16.65	3.98	-
Operating Expenses	8,089	7,680	5,901	7,135
Operating Income	-7,089	-6,680	-5,901	-7,162
Interest Expense	-1,559	-1,555	-1,617	-1,095
Interest & Investment Income	54.66	49.9	35.9	61.64
Currency Exchange Gain (Loss)	-1.23	-2.9	-0.95	-0.01
Other Non Operating Income (Expenses)	-4,771	-4,812	-3,019	-2,461
EBT Excluding Unusual Items	-13,365	-13,000	-10,502	-10,656
Gain (Loss) on Sale of Assets	-1.42	-1.42	-	-15.64
Asset Writedown	-	-	-	-30
Pretax Income	-13,367	-13,001	-10,502	-10,702
Net Income	-13,367	-13,001	-10,502	-10,702
Net Income to Common	-13,367	-13,001	-10,502	-10,702
Shares Outstanding (Basic)	8	8	6	6
Shares Outstanding (Diluted)	8	8	6	6
Shares Change (YoY)	-	16.65%	6.70%	-
EPS (Basic)	-1637.42	-1721.79	-1622.43	-1763.99
EPS (Diluted)	-1637.42	-1721.79	-1622.43	-1764.00
Free Cash Flow	-7,205	-6,686	-4,300	-7,046
Free Cash Flow Per Share	-882.61	-885.51	-664.32	-1161.34
Gross Margin	100.00%	100.00%	-	-
Operating Margin	-708.92%	-668.02%	-	-
Profit Margin	-1336.67%	-1300.12%	-	-
Free Cash Flow Margin	-720.50%	-668.64%	-	-
EBITDA	-6,642	-6,252	-5,578	-6,871
D&A For EBITDA	447.28	428.34	322.39	290.92
EBIT	-7,089	-6,680	-5,901	-7,162

Source: S&P Capital IQ. Standard template. Financial Sources.